# Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Study · id `cardio:ct-nct07041281` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07041281](<https://clinicaltrials.gov/study/NCT07041281>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07041281

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

## Technical summary

Registry record NCT07041281. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-16 (actual); primary completion 2027-12-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 204 participants (planned count; ClinicalTrials.gov record NCT07041281, source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)
- Started: 2025-10-16 (actual) (ClinicalTrials.gov record NCT07041281, source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)
- Primary completion: 2027-12-02 (anticipated) (ClinicalTrials.gov record NCT07041281, source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)
- Completion: 2029-03-02 (anticipated) (ClinicalTrials.gov record NCT07041281, source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07041281, source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07041281-2026-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
- Acronym: IMPACT-HT
- Condition: Preeclampsia
- Condition: Gestational Hypertension
- Intervention (Drug): spironolactone 25 mg orally once daily
- Intervention (Drug): Placebo tablet to match spironolactone
- Lead sponsor: Massachusetts General Hospital
- Lead sponsor class: OTHER
- Collaborator: Brigham and Women's Hospital
- Collaborator class: OTHER
- Collaborator: University of Pittsburgh Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)
- Registry lists this organization as a collaborator: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: University of Pittsburgh Medical Center (`cardio:org-university-of-pittsburgh-medical-center`)

## Provenance

Content hash: fa9a91aa24fb75f305af0d30f6f17034be3269c1f26f2c15c143ad169a8aa99c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
